Ruple, while in the care of New York City's renowned Memorial Sloan Kettering Cancer Center, swallowed the first three ...

An investigational anticoagulant that targets factor XI failed to prevent arteriovenous graft (AVG) thrombosis in chronic hemodialysis patients ... for the 6-mg group (HR 0.93, 95% CI 0.52-1. ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs ...

which is designed to assess its potential benefit in early breast cancer patients with high risk of recurrence." In addition, the company will be presenting other data at the ASCO Annual Meeting.

Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present updated preliminary efficacy and ...

“We have convened a meeting of all departmental heads. The patients who died on Tuesday (June 3, 2025) night were admitted to the hospital in a critical condition. Prima facie, the deaths seem ...

With the benefits rivaling some drugs, experts said cancer centers and insurance plans should consider making exercise ...

These data highlight elacestrant's potential role as an endocrine therapy backbone in combination with various targeted agents for patients with ER+/HER2- mBC. The robust elacestrant clinical ...

With the FDA approval of retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, researchers are now focusing on resistance mechanisms and future therapies, ...

Around 320 patients a week may have died avoidably in England last year due to excessive waits for hospital beds in Accident ... of the All-Party Parliamentary Group (APPG) on Emergency Care ...